Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Potent and reversible open-channel blocker of NMDA receptor derived from dizocilpine with enhanced membrane-to-channel inhibition

A. Misiachna, J. Konecny, M. Kolcheva, M. Ladislav, L. Prchal, J. Netolicky, S. Kortus, P. Zahumenska, E. Langore, M. Novak, K. Hemelikova, Z. Hermanova, M. Hrochova, A. Pelikanova, J. Odvarkova, J. Pejchal, J. Kassa, J. Zdarova Karasova, J....

. 2024 ; 178 (-) : 117201. [pub] 20240724

Language English Country France

Document type Journal Article

N-methyl-D-aspartate receptors (NMDARs) play a significant role in developing several central nervous system (CNS) disorders. Currently, memantine, used for treating Alzheimer's disease, and ketamine, known for its anesthetic and antidepressant properties, are two clinically used NMDAR open-channel blockers. However, despite extensive research into NMDAR modulators, many have shown either harmful side effects or inadequate effectiveness. For instance, dizocilpine (MK-801) is recognized for its powerful psychomimetic effects due to its high-affinity and nearly irreversible inhibition of the GluN1/GluN2 NMDAR subtypes. Unlike ketamine, memantine and MK-801 also act through a unique, low-affinity "membrane-to-channel inhibition" (MCI). We aimed to develop an open-channel blocker based on MK-801 with distinct inhibitory characteristics from memantine and MK-801. Our novel compound, K2060, demonstrated effective voltage-dependent inhibition in the micromolar range at key NMDAR subtypes, GluN1/GluN2A and GluN1/GluN2B, even in the presence of Mg2+. K2060 showed reversible inhibitory dynamics and a partially trapping open-channel blocking mechanism with a significantly stronger MCI than memantine. Using hippocampal slices, 30 μM K2060 inhibited excitatory postsynaptic currents in CA1 hippocampal neurons by ∼51 %, outperforming 30 μM memantine (∼21 % inhibition). K2060 exhibited No Observed Adverse Effect Level (NOAEL) of 15 mg/kg upon intraperitoneal administration in mice. Administering K2060 at a 10 mg/kg dosage resulted in brain concentrations of approximately 2 μM, with peak concentrations (Tmax) achieved within 15 minutes. Finally, applying K2060 with trimedoxime and atropine in mice exposed to tabun improved treatment outcomes. These results underscore K2060's potential as a therapeutic agent for CNS disorders linked to NMDAR dysfunction.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24019082
003      
CZ-PrNML
005      
20241024111627.0
007      
ta
008      
241015e20240724fr f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.biopha.2024.117201 $2 doi
035    __
$a (PubMed)39053419
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a fr
100    1_
$a Misiachna, Anna $u Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, Prague 4 14200, Czech Republic
245    10
$a Potent and reversible open-channel blocker of NMDA receptor derived from dizocilpine with enhanced membrane-to-channel inhibition / $c A. Misiachna, J. Konecny, M. Kolcheva, M. Ladislav, L. Prchal, J. Netolicky, S. Kortus, P. Zahumenska, E. Langore, M. Novak, K. Hemelikova, Z. Hermanova, M. Hrochova, A. Pelikanova, J. Odvarkova, J. Pejchal, J. Kassa, J. Zdarova Karasova, J. Korabecny, O. Soukup, M. Horak
520    9_
$a N-methyl-D-aspartate receptors (NMDARs) play a significant role in developing several central nervous system (CNS) disorders. Currently, memantine, used for treating Alzheimer's disease, and ketamine, known for its anesthetic and antidepressant properties, are two clinically used NMDAR open-channel blockers. However, despite extensive research into NMDAR modulators, many have shown either harmful side effects or inadequate effectiveness. For instance, dizocilpine (MK-801) is recognized for its powerful psychomimetic effects due to its high-affinity and nearly irreversible inhibition of the GluN1/GluN2 NMDAR subtypes. Unlike ketamine, memantine and MK-801 also act through a unique, low-affinity "membrane-to-channel inhibition" (MCI). We aimed to develop an open-channel blocker based on MK-801 with distinct inhibitory characteristics from memantine and MK-801. Our novel compound, K2060, demonstrated effective voltage-dependent inhibition in the micromolar range at key NMDAR subtypes, GluN1/GluN2A and GluN1/GluN2B, even in the presence of Mg2+. K2060 showed reversible inhibitory dynamics and a partially trapping open-channel blocking mechanism with a significantly stronger MCI than memantine. Using hippocampal slices, 30 μM K2060 inhibited excitatory postsynaptic currents in CA1 hippocampal neurons by ∼51 %, outperforming 30 μM memantine (∼21 % inhibition). K2060 exhibited No Observed Adverse Effect Level (NOAEL) of 15 mg/kg upon intraperitoneal administration in mice. Administering K2060 at a 10 mg/kg dosage resulted in brain concentrations of approximately 2 μM, with peak concentrations (Tmax) achieved within 15 minutes. Finally, applying K2060 with trimedoxime and atropine in mice exposed to tabun improved treatment outcomes. These results underscore K2060's potential as a therapeutic agent for CNS disorders linked to NMDAR dysfunction.
650    _2
$a zvířata $7 D000818
650    12
$a dizocilpinmaleát $x farmakologie $7 D016291
650    12
$a receptory N-methyl-D-aspartátu $x antagonisté a inhibitory $x metabolismus $7 D016194
650    _2
$a myši $7 D051379
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a antagonisté excitačních aminokyselin $x farmakologie $7 D018691
650    _2
$a lidé $7 D006801
650    _2
$a memantin $x farmakologie $7 D008559
650    _2
$a neurony $x účinky léků $x metabolismus $7 D009474
650    _2
$a myši inbrední C57BL $7 D008810
650    _2
$a excitační postsynaptické potenciály $x účinky léků $7 D019706
650    _2
$a hipokampus $x účinky léků $x metabolismus $7 D006624
655    _2
$a časopisecké články $7 D016428
700    1_
$a Konecny, Jan $u University Hospital Hradec Kralove, Biomedical Research Center, Sokolska 581, Hradec Kralove 500 05, Czech Republic; University of Defense, Military Faculty of Medicine, Department of Toxicology and Military Pharmacy, Trebesska 1575, Hradec Kralove 50005, Czech Republic
700    1_
$a Kolcheva, Marharyta $u Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, Prague 4 14200, Czech Republic
700    1_
$a Ladislav, Marek $u Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, Prague 4 14200, Czech Republic
700    1_
$a Prchal, Lukas $u University Hospital Hradec Kralove, Biomedical Research Center, Sokolska 581, Hradec Kralove 500 05, Czech Republic
700    1_
$a Netolicky, Jakub $u Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, Prague 4 14200, Czech Republic
700    1_
$a Kortus, Stepan $u Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, Prague 4 14200, Czech Republic
700    1_
$a Zahumenska, Petra $u Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, Prague 4 14200, Czech Republic
700    1_
$a Langore, Emily $u Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, Prague 4 14200, Czech Republic
700    1_
$a Novak, Martin $u University Hospital Hradec Kralove, Biomedical Research Center, Sokolska 581, Hradec Kralove 500 05, Czech Republic
700    1_
$a Hemelikova, Katarina $u Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, Prague 4 14200, Czech Republic
700    1_
$a Hermanova, Zuzana $u Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, Prague 4 14200, Czech Republic
700    1_
$a Hrochova, Michaela $u Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, Prague 4 14200, Czech Republic
700    1_
$a Pelikanova, Anezka $u Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, Prague 4 14200, Czech Republic
700    1_
$a Odvarkova, Jitka $u University Hospital Hradec Kralove, Biomedical Research Center, Sokolska 581, Hradec Kralove 500 05, Czech Republic; University of Defense, Military Faculty of Medicine, Department of Toxicology and Military Pharmacy, Trebesska 1575, Hradec Kralove 50005, Czech Republic
700    1_
$a Pejchal, Jaroslav $u University of Defense, Military Faculty of Medicine, Department of Toxicology and Military Pharmacy, Trebesska 1575, Hradec Kralove 50005, Czech Republic
700    1_
$a Kassa, Jiri $u University of Defense, Military Faculty of Medicine, Department of Toxicology and Military Pharmacy, Trebesska 1575, Hradec Kralove 50005, Czech Republic
700    1_
$a Zdarova Karasova, Jana $u University Hospital Hradec Kralove, Biomedical Research Center, Sokolska 581, Hradec Kralove 500 05, Czech Republic; University of Defense, Military Faculty of Medicine, Department of Toxicology and Military Pharmacy, Trebesska 1575, Hradec Kralove 50005, Czech Republic
700    1_
$a Korabecny, Jan $u University Hospital Hradec Kralove, Biomedical Research Center, Sokolska 581, Hradec Kralove 500 05, Czech Republic; University of Defense, Military Faculty of Medicine, Department of Toxicology and Military Pharmacy, Trebesska 1575, Hradec Kralove 50005, Czech Republic
700    1_
$a Soukup, Ondrej $u University Hospital Hradec Kralove, Biomedical Research Center, Sokolska 581, Hradec Kralove 500 05, Czech Republic; University of Defense, Military Faculty of Medicine, Department of Toxicology and Military Pharmacy, Trebesska 1575, Hradec Kralove 50005, Czech Republic. Electronic address: ondrej.soukup@fnhk.cz
700    1_
$a Horak, Martin $u Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, Prague 4 14200, Czech Republic. Electronic address: martin.horak@iem.cas.cz
773    0_
$w MED00005486 $t Biomedicine & pharmacotherapy Biomedecine & pharmacotherapie $x 1950-6007 $g Roč. 178 (20240724), s. 117201
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39053419 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20241015 $b ABA008
991    __
$a 20241024111621 $b ABA008
999    __
$a ok $b bmc $g 2201728 $s 1231055
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 178 $c - $d 117201 $e 20240724 $i 1950-6007 $m Biomedicine & pharmacotherapy Biomedecine & pharmacotherapie $n Biomed Pharmacother $x MED00005486
LZP    __
$a Pubmed-20241015

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...